LYNX

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Muscular dystrophy, Research, American Heart Association, Education, R9, MESA, Ageing, Fast Track, NSAA, McArdle, DUNE, Myopathy, Therapy, WMS, LYNX, ODD, Safety, Biomarker, Pharmacokinetics, HCM, Clinical trial, Caregiver, FOX, FDA, Muscle contraction, Engagement, Duchenne muscular dystrophy, ARCH, Administration, Patient, Disease, Pharmaceutical industry

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.
  • “In 2023, we made tremendous progress advancing our novel muscle-targeted therapeutics in the clinic,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.
  • Research and development (R&D) expenses were $27.7 million for the fourth quarter of 2023, compared to $23.8 million for the immediately preceding quarter.
  • General and Administrative (G&A) expenses were $6.2 million for the fourth quarter of 2023, compared to $5.7 million for the immediately preceding quarter.

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

Retrieved on: 
Tuesday, February 13, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Becker muscular dystrophy, Fast Track, Therapy, LYNX, FOX, Food, ODD, Survival, Ageing, Pharmaceutical industry

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
  • EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
  • The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
  • “Every day is important for individuals living with Duchenne and their families, and we are pleased that the FDA granted Fast Track designation,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, McArdle, Ageing, MESA, Therapy, Muscular dystrophy, ARCH, FOX, HCM, LYNX, LGMD, Myopathy, Conference, Safety, FDA, Webcast, Biomarker, Food and Drug Administration, Exercise, Pharmacokinetics, Pharmaceutical industry

Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.

Key Points: 
  • Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.
  • MESA will provide continued access to EDG-5506 treatment to study participants who were previously enrolled in Edgewise studies.
  • Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
    Edgewise will webcast its presentation today from the J.P. Morgan 42nd Annual Healthcare Conference at 10:30 am PT (1:30 pm ET).
  • A replay of the webcast will be available on Edgewise’s website for a limited time following the conference.

Lyndra Therapeutics Raises $101 Million in Series E Funding

Retrieved on: 
Thursday, December 21, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Sun Pharma, LYNX, Reuters, Risperidone, MIT, Polaris Partners, Engineering, Pharmaceutical industry

Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced the closing of a $101 million Series E financing round.

Key Points: 
  • Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced the closing of a $101 million Series E financing round.
  • Lyndra’s investigational therapies are enabled by the company’s LYNX® drug delivery platform, which creates long-acting oral medicines that can be taken once weekly.
  • The platform originated from the Bob Langer and Gio Traverso Laboratories at MIT, with which Lyndra has an exclusive technology license.
  • The round follows a $20.3 million Series D financing led by Polaris Partners that was completed in June 2023.

Lynx Software Technologies Announces Acquisition of Timesys Corporation

Retrieved on: 
Tuesday, December 12, 2023
Professional Services, Security, Technology, Mobile, Wireless, Software, Networks, Consulting, Lynx Software Technologies, Economics, Acquisition, LYNX, M&A, Risk management, Lynx, Linux

Lynx Software Technologies (Lynx) , a leader in the development of foundational, open architecture software solutions for the Mission Critical Edge, today announced the acquisition of Timesys Corporation (Timesys) , a provider of development tools, cybersecurity solutions, and differentiated software engineering services for open-source embedded and edge software applications.

Key Points: 
  • Lynx Software Technologies (Lynx) , a leader in the development of foundational, open architecture software solutions for the Mission Critical Edge, today announced the acquisition of Timesys Corporation (Timesys) , a provider of development tools, cybersecurity solutions, and differentiated software engineering services for open-source embedded and edge software applications.
  • For over 20 years, Timesys has been an industry leader, helping customers build, secure, test, and maintain Linux-based and other open-source edge and embedded software solutions.
  • “Lynx’s mission is to improve the economics of designing, deploying, and servicing high-assurance edge software solutions,” commented Tim Reed , Chief Executive Officer of Lynx.
  • I’m thrilled to welcome the Timesys team to the Lynx family.”
    The combination of Lynx and Timesys creates a scaled software solution provider focused on Mission Critical Edge and embedded software applications for customers with the most demanding reliability, security, and interoperability needs.

Clevertouch by Boxlight Opens Central European Hub Showroom

Retrieved on: 
Friday, November 17, 2023
Technology, Audio, Video, Other Professional Services, Public Safety, Training, Other Education, Professional Services, University, Other Technology, Primary, Secondary, Telecommunications, Education, Networks, Hardware, Corporation, Cleverlance Enterprise Solutions, LYNX, IMPACT, Communication

Boxlight Corporation (Nasdaq: BOXL), a leader in interactive technology, digital signage, classroom audio, campus communication, and services, announces that Clevertouch has opened a new central European Showroom in Dusseldorf, Germany.

Key Points: 
  • Boxlight Corporation (Nasdaq: BOXL), a leader in interactive technology, digital signage, classroom audio, campus communication, and services, announces that Clevertouch has opened a new central European Showroom in Dusseldorf, Germany.
  • Clevertouch continues to strengthen its position and presence on the European mainland with this new central EU hub.
  • Conveniently located in Dusseldorf, the new hub is easily accessible to all partners and end users across Europe.
  • Clevertouch, a leading provider of multi-award-winning interactive displays and digital signage solutions for both business and education, is set to showcase its cutting-edge technology in a showroom environment.

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, LYNX, Research, FOX, DUNE, Ageing, Education, Biomarker, Muscular dystrophy, Muscular Dystrophy Association, NSAA, G&A, Myopathy, Glycogen storage disease type V, American Heart Association, WMS, R, Muscle contraction, Pharmacokinetics, Dystrophinopathy, Disorder, Glycogen, PK, Clinical trial, Duchenne muscular dystrophy, McArdle, Safety, HCM, Therapy, Patient, MESA, R9, Administration, Pharmaceutical industry, Edgewise, Duchenne, Becker

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.

Key Points: 
  • Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.
  • “I’m thrilled with the progress we’ve made in 2023 across our skeletal and cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.
  • Research and development (R&D) expenses were $23.8 million for the third quarter of 2023, compared to $19.6 million for the immediately preceding quarter.
  • General and Administrative (G&A) expenses were $5.7 million for the third quarter of 2023, compared to $5.8 million for the immediately preceding quarter.

Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)

Retrieved on: 
Thursday, October 26, 2023
Research, Pharmaceutical, People with Disabilities, Consumer, Genetics, Teens, Children, Clinical Trials, Science, Biotechnology, FDA, Health, Steroid, LYNX, FOX, Adolescence, Ageing, MDA, Biomarker, University of Florida, NSAA, Myopathy, Pharmacokinetics, Dystrophinopathy, PK, University, Safety, Therapy, Patient, Pharmaceutical industry, Edgewise, Duchenne

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced an expansion of their clinical development program of EDG-5506, an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced an expansion of their clinical development program of EDG-5506, an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne.
  • The Company is initiating FOX, a new Phase 2 placebo-controlled trial in children and adolescent boys with Duchenne who have been previously treated with gene therapy.
  • The FOX trial will assess the effect of EDG-5506 over 12 weeks on safety, pharmacokinetics (PK) and biomarkers of muscle damage.
  • The study will also explore changes in functional measures, such as the North Star Ambulatory Assessment (NSAA) and self-reported/caregiver-reported outcomes.

Boxlight Solutions Win 9 Tech & Learning Best for Back to School Awards

Retrieved on: 
Tuesday, September 19, 2023
Apps, Applications, Wearables, Mobile Technology, Technology, Other Technology, Software, Audio, Video, Other Education, Hardware, Robotics, Education, Android 11, Learning, Educational technology, Communication, LYNX, Speech, Cleverlance Enterprise Solutions, Teaching, Curriculum, Mimio, Privacy, Google Classroom, School, Student, Corporation, Solo, Investment, ESSER, AI, Hygiene, System, Family, Whiteboard, Safety, Wireless, Television, Tutoring, Toy, Auction

Boxlight Corporation (Nasdaq: BOXL), a leading provider of interactive technology, digital signage, classroom audio, campus communication, and services today announces that it won a total of 9 Best for Back to School Awards by Tech and Learning.

Key Points: 
  • Boxlight Corporation (Nasdaq: BOXL), a leading provider of interactive technology, digital signage, classroom audio, campus communication, and services today announces that it won a total of 9 Best for Back to School Awards by Tech and Learning.
  • As schools continue to prepare and identify needs for the 2023-24 school year, Tech & Learning's Awards of Excellence program, "The Best Tools for Back to School," serves as a guide for readers, helping them discover the products and solutions that support their work in various learning environments.
  • Boxlight earned awards in both Primary and Secondary categories:
    Transform spaces with MimioWall Android digital displays.
  • For a complete list of this year’s Tech and Learning Awards of Excellence Best for Back to School winners, click here .

North Carolina Department of Transportation and Beep Launch Autonomous Shuttle Pilot Project at UNC Charlotte

Retrieved on: 
Thursday, September 7, 2023
North Carolina Department of Transportation, Learning, University of North Carolina at Charlotte, Town, Partnership, University, UNC, LYNX, Blue Line, Research, Four Stops and Home, Student, Lynx Blue Line, NCDOT, CASSI, Central Park, Environment, Transport, Beep

LAKE NONA, Fla., Sept. 7, 2023 /PRNewswire/ -- Beep Inc., a leading provider of autonomous and electric shared mobility solutions, today announced a second project with the North Carolina Department of Transportation (NCDOT) as part of its Connected Autonomous Shuttle Supporting Innovation (CASSI) program. The project brings shared autonomous mobility to the University of North Carolina at Charlotte (UNC Charlotte), showcasing the role of advanced technology in clean, connected campus transportation. The six-month pilot project will enable NCDOT and the university's faculty, staff and students to research and evaluate the vehicle and service in a real-world, campus environment.

Key Points: 
  • LAKE NONA, Fla., Sept. 7, 2023 /PRNewswire/ -- Beep Inc., a leading provider of autonomous and electric shared mobility solutions, today announced a second project with the North Carolina Department of Transportation (NCDOT) as part of its Connected Autonomous Shuttle Supporting Innovation (CASSI) program.
  • The project brings shared autonomous mobility to the University of North Carolina at Charlotte (UNC Charlotte), showcasing the role of advanced technology in clean, connected campus transportation.
  • "This project reflects a commitment from UNC Charlotte and NCDOT to use new and advanced technologies to improve public transportation and meet our future needs," said NCDOT Secretary Eric Boyette.
  • "We are proud that the North Carolina Department of Transportation has again placed its trust in Beep to play an ongoing role in the CASSI program statewide," said Beep CEO Joe Moye.